Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Colorized transmission electron micrograph of influenza A/H1N1 virus particles. The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

On March 31, 2025, the U.S. District Court for the Eastern District of Texas ruled that the Food and Drug Administration (FDA ...

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, ...

Teen nicotine pouch use nearly doubled from 2023 to 2024, raising health concerns and calls for targeted prevention and ...

Neuralink has received U.S. Food and Drug Administration's 'breakthrough' tag for its device to restore communication for ...

EHR companies' push for deregulation faces resistance from Microsoft.

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

The FDA plans to phase out eight artificial food dyes by the end of 2026 after Robert F. Kennedy has vocally opposed them.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...